low as $99 for a 100-count bottle in the United States. Pyrimethamine was approved as a generic in the United States in February 2020. In January 2020 the FTC filed a case against Vyera "alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim". A settlement was reached in December 2021. According to AP News, the settlement "requires Vyera and Phoenixus to provide up to $40 million in relief over 10 years to consumers who allegedly were fleeced by their actions and requires them to make Daraprim available to any potential generic competitor at the cost of producing the drug." According to Law360, company executive Kevin Mulleady "agreed to a seven-year ban on working for or holding more than an 8% share in most pharmaceutical companies." Other countries In India, over a dozen manufacturers sell pyrimethamine tablets, and multiple combinations of generic pyrimethamine are available for a price ranging from US$0.04 to US$0.10 each (3–7 rupees). In the UK, the same drug is available from GSK at a cost of US$20 (£13) for 30 tablets (about $0.66 each). In Australia, the drug is available in most pharmacies at a cost of US$9.35 (A$12.99) for 50 tablets (around US$0.18 each). In Brazil, the drug is available for R$0.07 a pill, or about US$0.02. In Canada, the drug was reportedly discontinued in 2013, but hospitals may make the drug in-house when it is needed. , Daraprim imported into Canada directly from GSK UK is available from an online pharmacy for US$2.20 per tablet. In Switzerland, the drug is available for US$9.45 (CHF9.05) for 30 tablets (around US$0.32 a piece). Research In 2011, researchers discovered that pyrimethamine can increase β-hexosaminidase activity, thus potentially slowing down the progression of late-onset Tay–Sachs disease. It is being evaluated in clinical trials as a treatment for amyotrophic lateral sclerosis. See also Sulfadoxine/pyrimethamine References External links Aminopyrimidines Antimalarial agents Chlorobenzenes Medical controversies Protozoal dihydrofolate reductase inhibitors World Health Organization essential medicines Wikipedia medicine articles ready to translate